Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02968004




Registration number
NCT02968004
Ethics application status
Date submitted
13/11/2016
Date registered
18/11/2016
Date last updated
9/02/2024

Titles & IDs
Public title
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Scientific title
A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
Secondary ID [1] 0 0
CP-4-006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pediatric Growth Hormone Deficiency 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other endocrine disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MOD-4023
Treatment: Drugs - Somatropin

Experimental: MOD-4023 - Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)

Active Comparator: Genotropin - Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)


Treatment: Drugs: MOD-4023
Once weekly subcutaneous injection using pre-filled pen device.

Treatment: Drugs: Somatropin
Once daily subcutaneous injection of Genotropin using pre-filled pen device.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annual Height Velocity
Timepoint [1] 0 0
52 weeks
Secondary outcome [1] 0 0
Height Velocity at 6 Months
Timepoint [1] 0 0
After 6 months of treatment
Secondary outcome [2] 0 0
Change in Height Standard Deviation Score (SDS)
Timepoint [2] 0 0
After 6 and 12 months
Secondary outcome [3] 0 0
Change in Bone Maturation (BM)
Timepoint [3] 0 0
52 weeks
Secondary outcome [4] 0 0
Insulin-like Growth Factor-1 (IGF-1) Standard Deviation Score (SDS)
Timepoint [4] 0 0
Baseline and at 12 months

Eligibility
Key inclusion criteria
Main Study

1. Pre-pubertal children aged =3 years , and not yet 11 years for girls or not yet 12
years for boys with either isolated GHD, or GH insufficiency as part of multiple
pituitary hormone deficiency.

2. Confirmed diagnosis of GHD by two different GH provocation tests defined as a peak
plasma GH level of =10 ng/mL.

3. Bone age (BA) is not older than chronological age and should be less than 10 for girls
and less than 11 for boys.

4. Without prior exposure to any r-hGH therapy (naïve patients).

5. Impaired height and height velocity defined as:

- Annualized height velocity (HV) below the 25th percentile for CA (HV < -0.7 SDS)
and gender according to sponsor calculator

- The interval between 2 height measurements should be at least 6 months, but
should not exceed 18 months prior to inclusion

6. Baseline IGF-I level of at least 1 SD below the mean IGF-1 level standardized for age
and sex (IGF-1 SDS =-1)

7. Normal calculated GFR per updated bedside Schwartz formula for pediatric patients

8. Children with multiple hormonal deficiencies must be on stable replacement therapies
(no change in dose) for other hypothalamo-pituitary-organ axes for at least 3 months
prior ICF signing

9. Normal 46XX karyotype for girls.

10. Willing and able to provide written informed consent of the parent or legal guardian
and written assent from patient

LT-OLE

11. Completion of the main study (12 months of treatment) with adequate compliance.

12. Willing and able to provide written informed consent of the parent or legal guardian
and written assent from patient

13. Agree to refrain from sexual activity

Main Study
Minimum age
3 Years
Maximum age
11 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Children with prior history of leukemia, lymphoma, sarcoma or any other forms of
cancer.

2. History of radiation therapy or chemotherapy

3. Malnourished children defined as BMI < -2 SDS for age and sex

4. Children with psychosocial dwarfism

5. Children born small for gestational age (SGA - birth weight and/or birth length <-2
SDS for gestational age)

6. Presence of anti-hGH antibodies at screening

7. Any clinically significant abnormality likely to affect growth or the ability to
evaluate growth, such as, but not limited to, chronic diseases like renal
insufficiency, spinal cord irradiation, etc.

8. T2 and T1 diabetic patients, who in the opinion of the investigator are not receiving
standard of care treatment or are non-compliant with their prescribed treatment or who
are in poor metabolic control.

9. Chromosomal abnormalities including Turner's syndrome, Laron syndrome, Noonan
syndrome, Prader-Willi syndrome, Russell-Silver syndrome, SHOX mutations/deletions and
skeletal dysplasias.

10. Concomitant administration of other treatments that may have an effect on growth such
as anabolic steroids, or sex steroids, with the exception of ADHD drugs or hormone
replacement therapies (thyroxin, hydrocortisone, desmopressin)

11. Children requiring glucocorticoid therapy (e.g. for asthma) that are taking
chronically a dose greater than 400 µg/d of inhaled budesonide or equivalent

12. Major medical conditions and/or presence of contraindication to r-hGH treatment.

13. More than one closed epiphyses

14. Known or suspected HIV-positive patient, or patient with advanced diseases such as
AIDS or tuberculosis.

15. Drug, substance, or alcohol abuse.

16. Known hypersensitivity to the components of study medication.

17. Other causes of short stature such as celiac disease, uncontrolled primary
hypothyroidism and rickets.

18. Likely non-compliance in respect to study conduct

19. Participation in any other trial of an investigational agent within 30 days prior to
consent

20. Study enrollment has been met or study is closed by sponsor prior to completion of
screening process.

LT-OLE

21. Concomitant administration of other treatments that may have an effect on growth such
as anabolic steroids, or sex steroids, with the exception of ADHD drugs or HRT
(thyroxin, hydrocortisone, desmopressin)

22. Change in medical condition during the treatment period (such as, but not limited to,
development of a serious inter-current critical illness, a severe adverse drug
reaction, etc.)

23. Positive pregnancy test

24. Unresolved drug related (Genotropin or MOD-4023) SAE from the treatment period as per
medical monitor judgement.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2024
Actual
Sample size
Target
Accrual to date
Final
224
Recruitment in Australia
Recruitment state(s)
NSW,WA
Recruitment hospital [1] 0 0
John Hunter Children's Hospital - New Lambton Heights
Recruitment hospital [2] 0 0
Children's Hospital at Westmead - Westmead
Recruitment hospital [3] 0 0
PM Hospital for Children - Subiaco
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Idaho
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Argentina
State/province [15] 0 0
Entre Rios
Country [16] 0 0
Argentina
State/province [16] 0 0
Córdoba
Country [17] 0 0
Belarus
State/province [17] 0 0
Minsk
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Varna
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
Colombia
State/province [20] 0 0
Bogotá
Country [21] 0 0
Colombia
State/province [21] 0 0
Medellín
Country [22] 0 0
Georgia
State/province [22] 0 0
Batumi
Country [23] 0 0
Georgia
State/province [23] 0 0
Tbilisi
Country [24] 0 0
Greece
State/province [24] 0 0
Athens
Country [25] 0 0
India
State/province [25] 0 0
Karnataka
Country [26] 0 0
India
State/province [26] 0 0
Maharashtra
Country [27] 0 0
India
State/province [27] 0 0
Punjab
Country [28] 0 0
India
State/province [28] 0 0
Telangna
Country [29] 0 0
India
State/province [29] 0 0
Nagpur
Country [30] 0 0
India
State/province [30] 0 0
New Delhi
Country [31] 0 0
Israel
State/province [31] 0 0
Afula
Country [32] 0 0
Israel
State/province [32] 0 0
Be'er Sheva
Country [33] 0 0
Israel
State/province [33] 0 0
Be'er Ya'aqov
Country [34] 0 0
Israel
State/province [34] 0 0
Haifa
Country [35] 0 0
Israel
State/province [35] 0 0
Jerusalem
Country [36] 0 0
Israel
State/province [36] 0 0
Petach Tikva
Country [37] 0 0
Israel
State/province [37] 0 0
Ramat Gan
Country [38] 0 0
Israel
State/province [38] 0 0
Re?ovot
Country [39] 0 0
Israel
State/province [39] 0 0
Tel Aviv
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Gyeonggi-do
Country [41] 0 0
Korea, Republic of
State/province [41] 0 0
Busan
Country [42] 0 0
Korea, Republic of
State/province [42] 0 0
Daegu
Country [43] 0 0
Korea, Republic of
State/province [43] 0 0
Gwangju
Country [44] 0 0
Korea, Republic of
State/province [44] 0 0
Seoul
Country [45] 0 0
Mexico
State/province [45] 0 0
Reserva Territorial Atilxcayotl
Country [46] 0 0
New Zealand
State/province [46] 0 0
Auckland
Country [47] 0 0
New Zealand
State/province [47] 0 0
Wellington
Country [48] 0 0
Poland
State/province [48] 0 0
Gdansk
Country [49] 0 0
Poland
State/province [49] 0 0
Lódz
Country [50] 0 0
Russian Federation
State/province [50] 0 0
Bashlortostan Republic
Country [51] 0 0
Russian Federation
State/province [51] 0 0
Tatarstan Republic
Country [52] 0 0
Russian Federation
State/province [52] 0 0
Moscow
Country [53] 0 0
Russian Federation
State/province [53] 0 0
Saint Petersburg
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Voronezh
Country [55] 0 0
Spain
State/province [55] 0 0
Aragon
Country [56] 0 0
Spain
State/province [56] 0 0
Cataluna
Country [57] 0 0
Spain
State/province [57] 0 0
Navarra
Country [58] 0 0
Spain
State/province [58] 0 0
Oviedo
Country [59] 0 0
Spain
State/province [59] 0 0
Sabadell
Country [60] 0 0
Spain
State/province [60] 0 0
Santiago De Compostela
Country [61] 0 0
Taiwan
State/province [61] 0 0
Taipei
Country [62] 0 0
Ukraine
State/province [62] 0 0
Kyiv
Country [63] 0 0
Ukraine
State/province [63] 0 0
Odesa
Country [64] 0 0
Ukraine
State/province [64] 0 0
Vinnitsa
Country [65] 0 0
Ukraine
State/province [65] 0 0
Zaporizhzhya
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Glasgow
Country [67] 0 0
United Kingdom
State/province [67] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
OPKO Health, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This will be an open-label, randomized, multicenter, efficacy and safety study of weekly
MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone
deficiency.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02968004
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Tony Cruz
Address 0 0
Sponsor GmbH
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02968004